TY - JOUR
T1 - Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist
T2 - A meta-analysis
AU - Jiao, Ruoyang
AU - Lin, Chu
AU - Cai, Xiaoling
AU - Wang, Jingxuan
AU - Wang, Yuan
AU - Lv, Fang
AU - Yang, Wenjia
AU - Ji, Linong
N1 - Publisher Copyright:
© 2024 John Wiley & Sons Ltd.
PY - 2024
Y1 - 2024
N2 - Aim: Diabetes is an independent risk factor for muscle mass loss, with possible mechanisms including impaired insulin signalling and chronic inflammation. The use of a glucagon-like peptide 1 (GLP-1) receptor-based agonist could lead to weight reduction, which might result from the loss of both fat and skeletal muscle. However, the body composition-modifying effects of GLP-1 receptor-based agonists have not been systematically characterized. Methods: PubMed, EMBASE, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltrial.gov were searched from inception to October 2023. Randomized controlled trials of GLP-1 receptor agonist or glucose-dependent insulinotropic polypeptide/GLP-1 receptor dual agonist, which reported the changes of body composition, were included. The results were computed as weighted mean differences (WMDs) and 95% confidence intervals (CIs) in a random-effects model. Results: In all, 19 randomized controlled trials were included. When compared with controls, substantial reductions in fat body mass were observed in patients using GLP-1 receptor-based agonist treatment (WMD = −2.25 kg, 95% CI −3.40 to −1.10 kg), with decrease in areas of both subcutaneous fat (WMD = −38.35 cm2, 95% CI, −54.75 to −21.95 cm2) and visceral fat (WMD = −14.61 cm2, 95% CI, −23.77 to −5.44 cm2). Moreover, greater reductions in lean body mass were also observed in GLP-1 receptor-based agonist users compared with non-users (WMD = −1.02 kg, 95% CI, −1.46 to −0.57 kg), while the changes in lean mass percentage were comparable between GLP-1 receptor-based agonist users and non-users. Conclusion: Compared with the controls, GLP-1 receptor-based agonist users experienced greater reductions in fat body mass, with body shaping effects in terms of both subcutaneous fat mass and visceral fat mass. Although greater reductions in lean body mass were also observed in GLP-1 receptor-based agonist users, the changes in lean mass percentage were comparable between the users and non-users.
AB - Aim: Diabetes is an independent risk factor for muscle mass loss, with possible mechanisms including impaired insulin signalling and chronic inflammation. The use of a glucagon-like peptide 1 (GLP-1) receptor-based agonist could lead to weight reduction, which might result from the loss of both fat and skeletal muscle. However, the body composition-modifying effects of GLP-1 receptor-based agonists have not been systematically characterized. Methods: PubMed, EMBASE, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltrial.gov were searched from inception to October 2023. Randomized controlled trials of GLP-1 receptor agonist or glucose-dependent insulinotropic polypeptide/GLP-1 receptor dual agonist, which reported the changes of body composition, were included. The results were computed as weighted mean differences (WMDs) and 95% confidence intervals (CIs) in a random-effects model. Results: In all, 19 randomized controlled trials were included. When compared with controls, substantial reductions in fat body mass were observed in patients using GLP-1 receptor-based agonist treatment (WMD = −2.25 kg, 95% CI −3.40 to −1.10 kg), with decrease in areas of both subcutaneous fat (WMD = −38.35 cm2, 95% CI, −54.75 to −21.95 cm2) and visceral fat (WMD = −14.61 cm2, 95% CI, −23.77 to −5.44 cm2). Moreover, greater reductions in lean body mass were also observed in GLP-1 receptor-based agonist users compared with non-users (WMD = −1.02 kg, 95% CI, −1.46 to −0.57 kg), while the changes in lean mass percentage were comparable between GLP-1 receptor-based agonist users and non-users. Conclusion: Compared with the controls, GLP-1 receptor-based agonist users experienced greater reductions in fat body mass, with body shaping effects in terms of both subcutaneous fat mass and visceral fat mass. Although greater reductions in lean body mass were also observed in GLP-1 receptor-based agonist users, the changes in lean mass percentage were comparable between the users and non-users.
KW - fat mass
KW - glucagon-like peptide 1
KW - lean mass
KW - sarcopenia
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85206913266&partnerID=8YFLogxK
U2 - 10.1111/dom.16012
DO - 10.1111/dom.16012
M3 - Article
C2 - 39431379
AN - SCOPUS:85206913266
SN - 1462-8902
VL - 27
SP - 259
EP - 267
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 1
ER -
